Semler Scientific (NASDAQ:SMLR) and Nexeon Medsystems (OTCMKTS:NXNN) Critical Survey

Semler Scientific (NASDAQ:SMLR) and Nexeon Medsystems (OTCMKTS:NXNN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation and Earnings

This table compares Semler Scientific and Nexeon Medsystems”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Semler Scientific	$56.29 million	5.77	$20.58 million	$4.91	6.89
Nexeon Medsystems	N/A	N/A	N/A	N/A	N/A

Semler Scientific has higher revenue and earnings than Nexeon Medsystems.

Risk and Volatility

Semler Scientific has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Nexeon Medsystems has a beta of 6.98, indicating that its stock price is 598% more volatile than the S&P 500.

Institutional and Insider Ownership

49.4% of Semler Scientific shares are owned by institutional investors. 30.2% of Semler Scientific shares are owned by company insiders. Comparatively, 61.2% of Nexeon Medsystems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Semler Scientific and Nexeon Medsystems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Semler Scientific	72.65%	50.77%	47.04%
Nexeon Medsystems	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations for Semler Scientific and Nexeon Medsystems, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Semler Scientific	0	0	1	0	3.00
Nexeon Medsystems	0	0	0	0	0.00

Semler Scientific presently has a consensus target price of $71.00, indicating a potential upside of 109.75%. Given Semler Scientific’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Semler Scientific is more favorable than Nexeon Medsystems.

Summary

Semler Scientific beats Nexeon Medsystems on 8 of the 10 factors compared between the two stocks.

About Semler Scientific

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company’s products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.

About Nexeon Medsystems

Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.